You Position: Home > Paper
Value of combination detection of serum CYFRA21-1 and NSE in the diagnosis of lung cancer
( views:204, downloads:12 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF MODERN CLINICAL MEDICAL BIOENGINEERING
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1008-634X.2007.01.010
- Key Word:
- 肺癌;YFRA21-1;神经元特异性烯醇化酶;血清
Abstract： 目的 探讨联合检测血清中肿瘤标记物CYFRA21-1、NSE对肺癌早期诊断、病情监测及疗效判定的价值.方法 将肺癌患者分为非小细胞肺癌组(NSCLC)和小细胞肺癌组(SCLC),以健康人及肺部良性病变患者(BLD)为对照组.静脉取血,采用免疫放射法(IRMA)、放射免疫法(RIA)分别检测血清CYFRA21-1和NSE.结果 血清CYFRA21-1水平在NSCLC组明显高于SCLC和BLD组(P＜0.01),其对NSCLC诊断的阳性率显著高于SCLC组(58.1%vs 16.7%,P＜0.01).NSE则在SCLC组明显高于NSCLC和BLD组(P＜0.01),其对SCLC诊断的阳性率为66.7%,显著高于NSCLC组24.3%(P＜0.01).血清CYFRA21-1、NSE联合检测与各单项指标相比,可将肺癌诊断的敏感度、特异度和阳性率分别提高到79.1%、91.7%和85.0%(P＜0.01).此外,在NSCLC组,血清CYFRA21-1含量变化与肿瘤分期呈正相关,且与患者病情的变化有相关性.结论 联合检测血清中CYFRA21-1、NSE水平可明显提高肺癌早期诊断的阳性率,从而提高肺癌的早期诊断.临床上动态监测血清CYFRA21-1水平对NSCLC的进程及疗效判断有一定的价值.
- [1]杨德昌,杨拴盈.肺癌诊断水平的现状与进展[J].2001,(8).
- [2]李承红,杨军,马丹,等.联合检测血清中CYFRA21-1、NSE对肺癌诊断和预后的意义[J].2002,(3).
- [3]王涛,李泽坚.CYFRA21-1在肿瘤诊治方面的研究[J].2002,(3).
- [4]A. Hamzaoui,P. Thomas,O. Castelnau,etc.Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring[J].1997,16(2-3).
- [5]Boher JM,Pujol JL,Grenier J,etc.Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.[J].2001,31(2).
- [6]Petra Stieber,Ute Hasholzner,Heinz Bodenmüller,etc.CYFRA 21-1: A new marker in lung cancer[J].1993,72(3).
- [7]Furst H,Seemann MD,Beinert T,etc.An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.[J].1999,26(3).
- [8]J L, Pujol,J, Grenier,J P, Daurès,etc.Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.[J].1993,53.
- [9]W A, Fry,H R, Menck,D P, Winchester.The National Cancer Data Base report on lung cancer.[J].1996,77(9).